文献速递糖尿病性腺与生殖内分泌

艾塞那肽、二甲双胍或联合治疗PCOS糖尿病前期:随机对照研究

Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该随机开放平行对照研究纳入PCOS合并糖尿病前期患者,比较艾塞那肽(EX)、二甲双胍(MET)及联合(COM)治疗12周后持续缓解率。

要点

  • PCOS合并糖尿病前期患者中,艾塞那肽或联合治疗12周后持续缓解率高于二甲双胍单药。
  • 艾塞那肽较二甲双胍更有效抑制OGTT2小时血糖增量,并改善餐后胰岛素分泌。
  • 糖耐量受损是PCOS糖尿病前期的主要表型,总体持续缓解率为50.7%。

核心结论

  • 与二甲双胍单药相比,艾塞那肽或艾塞那肽联合二甲双胍通过改善餐后胰岛素分泌,在PCOS糖尿病前期患者中实现更高的持续缓解率。

研究设计与样本

  • 随机、开放标签、平行组对照试验,纳入PCOS合并糖尿病前期患者(空腹血糖5.6-6.9 mmol/L和/或OGTT 2小时血糖7.8-11.0 mmol/L),183例入组中150例完成研究。
  • 干预为艾塞那肽(10-20μg/日)、二甲双胍(1500-2000 mg/日)或联合治疗12周。

主要发现

  • 总体持续糖尿病前期缓解率为50.7%。
  • 艾塞那肽对OGTT 2小时血糖增量的抑制优于二甲双胍。
  • 两步高糖钳夹试验显示艾塞那肽较二甲双胍增加餐后胰岛素分泌,可能解释更高的缓解率。

关键数值与推荐

  • 糖尿病前期诊断标准:空腹血糖5.6-6.9 mmol/L和/或OGTT 2小时血糖7.8-11.0 mmol/L。
  • 主要终点为持续缓解率:治疗12周后停药洗脱12周,OGTT恢复正常。

临床怎么用

  • 对于PCOS合并糖尿病前期患者,可考虑艾塞那肽或艾塞那肽联合二甲双胍以改善餐后胰岛素分泌并提高糖尿病前期缓解率。
  • 二甲双胍单药治疗的持续缓解率较低,临床决策时可结合患者情况选择治疗方案。

局限性

  • 研究为开放标签设计,可能引入偏倚。
  • 样本量有限(150例完成),随访时间较短(12周治疗+12周洗脱)。
  • 研究人群为PCOS合并糖尿病前期患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Up to 40% of patients with polycystic ovary syndrome (PCOS) have prediabetes; an optimal pharmacotherapy regimen for diabetes prevention in PCOS is yet to be established. OBJECTIVE: To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS. DESIGN: Randomized, open-label, parallel-group controlled trial. SETTING: Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine. PATIENTS: PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]). A total of 150 out of 183 eligible enrollees completed the study. INTERVENTION: EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks. MAIN OUTCOME MEASURES: Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic β-cell function parameters (secondary endpoints) and potential mechanisms were assessed. RESULTS: Impaired glucose tolerance was found the dominant prediabetes phenotype. Overall sustained prediabetes remission rate was 50.7%. Remission rate of COM group (64%, 32/50) or EX group (56%, 28/50) was significantly higher than that of the MET group (32%, 16/50) (P = .003 and .027, respectively). EX was associated with superior suppression of 2-hour glucose increment in OGTT. A 2-step hyperglycemic clamp study revealed that EX had led to higher postprandial insulin secretion than MET, potentially explaining the higher remission rate. CONCLUSIONS: Compared with MET monotherapy, EX or COM achieved higher rate of remission of prediabetes among PCOS patients by improving postprandial insulin secretion.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tao T, Zhang Y, Zhu YC, et al. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab. 2021. PMID: 32995892. doi:10.1210/clinem/dgaa692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。